StocksFin Logo
BeiGene, Ltd. country of incorporation
|
|
Mr. John V. Oyler
|
9,000 employees
NASDAQ | Healthcare | Biotechnology
Bio-Techne Corporation country of incorporation
|
|
Mr. Charles Kummeth
|
3,000 employees
NASDAQ | Healthcare | Biotechnology
Q322 reported Nov 9, 2022 Reporting Period
$387.63M 87.8% vs. Q321 Revenues Q322
-29.74% 68.2% vs. Q321 Gross Profit Margin
-143.84% ! 28.3% vs. Q321 Net Profit Margin
-690.56M ! -39.3% vs. Q321 Free Cash Flow Q322
$-5.33 ! -20.6% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q123
0.11%
Q123 reported Nov 7, 2022 Reporting Period
$269.66M 4.6% vs. Q122 Revenues Q123
66.6% 0.4% vs. Q122 Gross Profit Margin
33.21% 22.9% vs. Q122 Net Profit Margin
46.53M -3.9% vs. Q122 Free Cash Flow Q123
$0.55 30.6% vs. Q122 EPS Q123
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q123
0.11%
Loading...
Loading...
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
3.74
2.74
Current Ratio
4.07
4.01
Cash Ratio
2.97
1.2
Price to Book
3
6.36
Price to Sales
35.99
41.32
Price to Earnings
-6.26
31.1